New Drugs 2009-2010- Pharmacist

  Price  

  Credits  2

This product is currently out of stock and unavailable.


Format
The year 2009 held big changes for the Food and Drug Administration (FDA). Proposals sent to Congress called for expanding the agency's budget to $3.2 billion. If enacted, this would be the largest annual budget increase in the FDA’s history. Margaret Hamburg, MD, was confirmed as the new FDA commissioner. Although it is too soon to tell, some experts believe that her new leadership team is likely to focus more on drug safety than on rapid new drug approvals. Recent legislation has expanded the agency's authority to require, rather than simply request, post-marketing safety studies from drug manufacturers. At the time of writing, a variety of new molecular entities had arrived on the market in 2009, but most were extensions of existing drug classes or “me-too” drugs. This article will focus on selected new drugs approved in 2009 that are likely to be of interest to the community-based practitioner including benzyl alcohol 5% (UlesfiaTM), dronedarone (Multaq®), febuxostat (Uloric®), pitavastatin (Livalo®), prasugrel (Effient®), saxagliptin (OnglyzaTM), tapentadol (NucyntaTM), iloperidone (FanaptTM), and asenapine (Saphris®). Each monograph summarizes the drug’s role in therapy, usual dose, precautions and drug interactions. Useful and practical patient counseling points are highlighted separately for easy access. Brief overviews for 8 additional new drugs are provided in a table. Other tables outline new formulations and new combination products you are likely to encounter in practice.

OR

Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Pharm/Nurse Drug Therapy

Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

Course Accreditation

  • Activity Type:
    Knowledge
  • CE Broker
  • Universal Activity Number:
    Pharmacist : 428-0000-10-003-H01-P
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.